Company profile for Byondis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Byondis we put cutting-edge science, ability to innovate and talented people into action to create precision medicines which provide the best possible outcomes for patients with relentless cancers and auto-immune diseases. Byondis focuses on development of innovative medicines, including antibody-drug conjugates, in two key therapeutic areas: oncology and autoimmune diseases. We provide a fair, human, open and inspiring ...
At Byondis we put cutting-edge science, ability to innovate and talented people into action to create precision medicines which provide the best possible outcomes for patients with relentless cancers and auto-immune diseases. Byondis focuses on development of innovative medicines, including antibody-drug conjugates, in two key therapeutic areas: oncology and autoimmune diseases. We provide a fair, human, open and inspiring working environment, with room for ambition, entrepreneurship and new initiatives - leading to new medicines with the potential to transform patients’ lives.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Microweg 22 P.O. Box 6570 6503 GB Nijmegen
Telephone
Telephone
+31 (0)24 679 5100
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250603807653/en/Byondis-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Novel-SIRP-Directed-Monoclonal-Antibody-BYON4228-in-Patients-With-Advanced-or-Metastatic-Solid-Tumors

BUSINESSWIRE
03 Jun 2025

https://www.businesswire.com/news/home/20250324077182/en/Byondis-Appoints-Christoph-Korpus-PhD-MBA-as-Chief-Business-Officer

BUSINESSWIRE
24 Mar 2025

https://www.businesswire.com/news/home/20241118767330/fr

BUSINESSWIRE
19 Nov 2024

https://www.businesswire.com/news/home/20241118495587/en

BUSINESSWIRE
19 Nov 2024

https://www.prnewswire.com/news-releases/us-food-and-drug-administration-issues-complete-response-letter-for-byondis-vic-trastuzumab-duocarmazine-301824573.html

PR NEWSWIRE
16 May 2023

https://www.prnewswire.com/news-releases/byondis-initiates-phase-i-study-of-next-generation-antibody-drug-conjugate-byon3521-301611571.html

PRNEWSWIRE
25 Aug 2022

ABOUT THIS PAGE

Contact Byondis and get a quotation

Byondis is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Duocarmazine bulk with DMF offered by Byondis

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty